R ARIVANANTHAM
CHENNAI, JUNE 10
In hospitals across the world, doctors are increasingly confronting a frightening enemy—bacteria that no longer respond to conventional antibiotics. Known as “superbugs,” these drug-resistant microorganisms have become one of humanity’s most serious health threats, silently claiming lives and rendering some of medicine’s most trusted treatments ineffective.
- US FDA approves Zaynich, the first fully developed and commercialised New Chemical Entity (NCE) from an Indian pharmaceutical company.
- Developed by Mumbai-based Wockhardt after nearly 14 years of research, the drug targets life-threatening drug-resistant “superbugs.”
- The breakthrough antibiotic offers fresh hope against antimicrobial resistance, one of the world’s fastest-growing public health threats.
- Medical experts urge responsible antibiotic use, warning that misuse could eventually weaken even this next-generation treatment.
Against this backdrop, a remarkable story of Indian scientific innovation is capturing global attention.
For the first time, a novel antibiotic discovered, developed and commercialised entirely by an Indian pharmaceutical company has received approval from the United States Food and Drug Administration. The drug, named Zaynich (cefepime-zidebactam), has been developed by Mumbai-headquartered Wockhardt and is being hailed as a major weapon against multidrug-resistant bacterial infections.
A 14-Year Scientific Journey
The approval is the culmination of nearly 14 years of intensive research by Indian scientists and researchers.
Unlike generic medicines, which replicate existing drugs, Zaynich represents a completely new therapeutic innovation. It is also the first New Chemical Entity fully developed and commercialised by an Indian pharmaceutical company to secure FDA approval—a milestone many experts view as a turning point for India’s pharmaceutical innovation ecosystem. (Drugs.com)
The antibiotic combines a fourth-generation cephalosporin, cefepime, with zidebactam, a first-in-class molecule designed to tackle highly resistant Gram-negative bacteria. (Drugs.com)
A Lifeline Against Deadly Superbugs
The drug is expected to play a crucial role in treating severe infections caused by dangerous bacteria such as:
- E. coli
- Klebsiella
- Pseudomonas
These pathogens are frequently responsible for hospital-acquired infections, severe pneumonia, bloodstream infections and complicated urinary tract infections.
What makes them particularly dangerous is their ability to evolve resistance against multiple antibiotics, leaving doctors with very few treatment options.
Clinical trials involving 530 patients across multiple countries demonstrated impressive results, with Zaynich achieving significantly higher cure rates compared to standard therapies while maintaining a favourable safety profile.
A Global Health Crisis in the Making
The significance of the breakthrough extends far beyond a single medicine.
Antimicrobial resistance (AMR) is increasingly being described as the next global pandemic.
Medical studies estimate that hundreds of thousands of deaths each year are linked to antibiotic-resistant infections. Without effective intervention, experts fear the toll could rise dramatically in coming decades.
For India, where antibiotic misuse remains widespread, the challenge is particularly acute.
Health experts warn that self-medication for common illnesses such as coughs, colds and viral fevers continues to accelerate resistance, making once-effective medicines increasingly powerless.
What Wockhardt’s Leadership Says
Welcoming the FDA approval, Dennis Deruelle, Chief Medical Officer, Wockhardt – US said:
“The threat of drug-resistant infections is an escalating crisis, leaving clinicians with fewer tools to treat patients facing these aggressive pathogens. The FDA approval of Zaynich is a monumental step forward in validating a new option for these underserved populations.”
The company believes the approval offers fresh hope to patients battling infections for which treatment choices have become increasingly limited.
Meanwhile, Dr Habil Khorakiwala, Chairman, Wockhardt Group described the achievement as a defining moment not just for his company but for India itself.
“This approval is a significant realization of our mission to provide patients with novel antibiotics that help to address one of the most urgent global health threats—antimicrobial resistance.”
He further added:
“Zaynich is the first New Chemical Entity fully developed and commercialized by an Indian pharmaceutical company to receive an FDA approval, representing a historic milestone not only for Wockhardt, but for the Indian pharmaceutical industry.”
The Real Battle Begins Now
Doctors caution that even the most advanced antibiotics can lose their effectiveness if used irresponsibly.
Every unnecessary antibiotic prescription, every instance of self-medication and every incomplete treatment course gives bacteria another opportunity to evolve resistance.
In other words, the future of Zaynich may depend not only on scientists and pharmaceutical companies but also on patients, healthcare providers and policymakers.
A Moment of Pride for Indian Science
For decades, India has been recognised as the “pharmacy of the world” because of its ability to manufacture affordable medicines.
With Zaynich, the country has demonstrated something even more powerful—the ability to innovate and create breakthrough medicines capable of addressing global health challenges.
As the world searches for new ways to fight antimicrobial resistance, this homegrown scientific triumph stands as a reminder that some of the most important solutions may emerge from Indian laboratories.
And in the battle against superbugs, India has just delivered one of its strongest weapons yet.
